This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 9 min This content is machine translated Psoriasis in locations that are difficult to treat New study data on IL-23 inhibition When psoriasis manifests in palmoplantar and intertriginous regions or on the nails, this often poses a therapeutic challenge. Several recently presented analyses on the effects of anti-IL-23p19 antibodies currently approved...…
View Post 9 min This content is machine translated System therapy for psoriasis Expanded possibilities thanks to practical innovations Compared to the past, there are now more and more effective systemic therapies available. This has been helped by a surge in innovation that has produced a wide range of…
View Post 5 min This content is machine translated Biologics therapy for psoriasis Better outcomes through innovative methods of therapy management Personalized medicine is also becoming increasingly important in the field of inflammatory skin diseases. Currently, IL-17 and IL-23 inhibitors are most effective in moderate to severe psoriasis, but the response…
View Post 8 min This content is machine translated Psoriasis vulgaris Practice-oriented recommendations for system therapy Fortunately, developments in recent years have led to the effective treatment of many patients with moderate to severe psoriasis. In addition to classical immunosuppressants, several biologics and a small molecule…
View Post 3 min This content is machine translated Guselkumab High response rate maintained over 4 years Recently presented long-term data from the VOYAGE 1 Phase III clinical trial demonstrate that 84% of patients continued to achieve PASI-90 at 204 weeks.
View Post 3 min This content is machine translated Risankizumab as a therapeutic option “Real life” interim balance: PASI 100 – realistic target Risankizumab has been approved in Switzerland since April 2019 for moderate to severe plaque psoriasis after unsuccessful therapy with conventional systemic treatment. The high and long-lasting efficacy with rapid response…
